Why Research Funding Cuts Are a Strategic Risk, Not a Budget Problem

When the federal government freezes research funding, leaders tend to treat it as a budget problem: a number that was cut and might later be restored. The harder truth in this conversation is that much of the damage cannot be undone. Halted studies, shuttered labs, and departed early-career researchers do not simply resume when the money comes back. Research funding cuts are a strategic risk, not a line item.

In this episode of the Changing Higher Ed® podcast, Dr. Drumm McNaughton speaks with Dr. Nick Dirks, President and CEO of the New York Academy of Sciences and former chancellor of UC Berkeley. Dirks first joined the show in 2018, as the podcast's third guest, reflecting on the protests that had put Berkeley at the center of national attention over controversial speakers on campus. He returns to discuss what the current research funding cuts are doing to American science, where AI fits in higher education, and the choices facing presidents and boards.

This conversation is especially relevant for presidents, provosts, and board members weighing how federal funding volatility, the loss of early-career research talent, and the rapid arrival of AI in the classroom should shape institutional strategy and risk planning.

Topics Covered •       Why frozen research funding cannot simply be switched back on, and what that means for biomedical studies, drug trials, and animal research

•       The damage to the early-career research pipeline, and why postdocs and graduate students are the most exposed

•       What current data shows about US scientists weighing whether to leave the country or the field

•       How the president's role has shifted from pleasing every constituency to making hard, unpopular choices

•       Why bringing higher education's costs down depends on faculty and administrators rebuilding trust

Real-World Examples Discussed •       Drug trials at Columbia that had to stop outright, ending years of work toward a potential cancer treatment that could not be restarted once funding returned

•       Animal research populations that universities could no longer afford to maintain, forcing some labs to shut down entirely

•       The mRNA vaccine effort spanning the University of Pennsylvania, Germany's BioNTech, and scientists originally from Turkey

•       A National Postdoctoral Association survey Dirks worked on, and a January 2026 AAU brief quantifying how far the talent loss has progressed